Stay updated with breaking news from Severe Atopic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting included multiple poster presentations featuring studies on atopic dermatitis, 2 of which focused on the impact of ruxolitinib cream monotherapy and educating managed care professionals.
This new data was presented at EADV in Berlin, with the findings of 3 studies expanding the range of effectiveness of this treatment to 140-weeks for patients with eczema.
New Positive Data From Phase 3 SPROUT Trial, Studying Otezla (apremilast) in Children Ages 6-17 With Moderate to Severe Plaque Psoriasis Positive ...
Analyses highlight long-term efficacy and safety results, including real-world data, from studies of SKYRIZI® (risankizumab) in moderate to severe...